Raphael Pharmaceutical (RAPH) Other Accumulated Expenses (2025)

Raphael Pharmaceutical (RAPH) reported Other Accumulated Expenses of $297700.0 for Q4 2025.

Raphael Pharmaceutical (RAPH) Other Accumulated Expenses (2025) Analysis & Trends

Raphael Pharmaceutical (RAPH) has 1 years of Other Accumulated Expenses data on file, last reported at $297700.0 in Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses changed N/A year-over-year to $297700.0; the trailing twelve-month figure through Dec 2025 stood at $297700.0 (changed N/A YoY), and the FY2025 full-year result was $297700.0, changed N/A from the prior year.
  • Other Accumulated Expenses steadied at $297700.0 in Q4 2025.
  • In the past five years, Other Accumulated Expenses ranged from a high of $297700.0 in Q4 2025 to a low of $297700.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 89.28 Bn 87.42 Bn -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn
10 Raphael Pharmaceutical 27.37 Mn 27.33 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 297,700.00